INNOVADERM CRO IS NOW INDERO.
READ THE ANNOUNCEMENT
Talk to us
circle

Eligibility Criteria for Active Ulcerative Pyoderma Gangrenosum (PG) in Clinical Trials: A Delphi Consensus on Behalf of the Understanding PG: Review and Assessment of Disease Effects (UPGRADE) Group

Multiple Authors

Multiple Authors

2023-12-16

SHARE THIS POST

Date:2023-12-16

Authors: Kamal K, Xia E, Li SJ, Alavi A, Cogen AL, Firooz A, Marzano AV, Kaffenberger BH, Sibbald C, Fernandez AP, Callen JP, Dissemond J, Renato V Gontijo J, Shams K, Gerbens LA, French LE, Gould LJ, Bissonnette R, Shaigany S, Tolkachjov S, Yamamoto T, Wei-Ting Huang W, Ortega-Loayza AG, Mostaghimi A

Category: Other

Abstract: At present, there are no standardized guidelines for determining patient eligibility for pyoderma gangrenosum (PG) clinical trials. Thus, we aim to determine which clinical features, histopathological features, or laboratory features should be included in active ulcerative PG clinical trial eligibility criteria for treatment-naïve patients and patients already treated with immunomodulating medications (treatment-exposed patients).

Read more on pubmed
SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.

3530 Saint-Laurent Boulevard
Suite 300

Montreal, QC, H2X 2V1, Canada

Operational Capabilities
  • North America
  • Europe
  • Asia Pacific
  • Latin America
EXPERTISE
OTHER THERAPEUTIC AREAS
STAGES
CRO SERVICES
About
Youtube X-twitter Linkedin

© 2025 Indero. All Rights Reserved. Privacy Policy. Designed and developed by Altitude Marketing.

logo mobile
Talk to us

Is Now

We are excited to announce that Innovaderm is rebranding our CRO division as Indero (in-dAIR-oh). This rebranding reflects our ongoing commitment to innovation and our expansion into the field of rheumatology, a therapeutic area closely linked to dermatology. As a dual-focus CRO specializing in both dermatology and rheumatology, this strategic decision marks a significant milestone for our organization, and we are eager to embark on this new chapter with our valued partners and clients. Additionally, our Clinical Research Unit (CRU) will keep the name Innovaderm and will continue to conduct dermatology studies.

Site Selection & Management

Our long-standing relationships with key opinion leaders and highly performing sites result in optimized start-up processes that deliver strong results in the least amount of time. As part of our site evaluation, our team utilizes past performance metrics, recruitment projections based on the competitive landscape, and detailed feasibility surveys to determine a site’s capabilities and interest in a study.

SEE SERVICES
Hands, tablet and contact us with healthcare marketing or advertising on a website in the medical industry.

Patient Recruitment

Our dedicated patient recruitment and advertising team integrates with the study team to tailor recruitment strategies, customize central ad campaigns, develop advertising creative, and continuously track and adapt recruitment goals. Our patient-centric approach is enhanced by Clinago, our technology enabled recruitment service.

SEE SERVICES

PROJECT MANAGEMENT

We orchestrate all study activities and deliverables, including the site selection process, budget and contract negotiations, patient engagement, and recruitment enrollment projections, all while respecting your study timelines.

SEE SERVICES
PROJECT MANAGEMENT

We orchestrate all study activities and deliverables, including the site selection process, budget and contract negotiations, patient engagement, and recruitment enrollment projections, all while respecting your study timelines.

SEE SERVICES